Gates Gives $40 mln to Boost Access to mRNA Vaccines in Africa
- The Gates Foundation is investing $40 million to support the production of mRNA vaccines in Africa, aiming to improve vaccine equity and build vaccine self-reliance on the continent.
- African manufacturers, including Institut Pasteur and Biovac, will use the mRNA research and manufacturing platform developed by Quantoom Biosciences to produce vaccines for diseases like Lassa fever and Rift Valley fever. This technology has the potential to make low- and middle-income countries more autonomous in terms of research and development.
- The Gates Foundation's investment also goes towards further advancing mRNA technology and lowering costs through the development of Ntensify, a manufacturing platform by Quantoom Biosciences.
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left9Leaning Right1Center16Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
61% Center
L 35%
C 61%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
